You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

December 2, 2024

Thailand’s Updated Guidelines on Kratom in Food and Herbal Products

Subscribe to Updates

Kratom (Mitragyna speciosa) was once listed as a prohibited substance under the Narcotics Act. Kratom was then removed from the narcotics list in 2021 and is now regulated under the Kratom Plant Act B.E. 2565 (2022), which allows the trading, use, import, and export of kratom. Furthermore, the Ministry of Public Health has allowed the use of kratom in food and drink, food supplements, and herbal products. Anyone who wishes to launch kratom food or herbal products must first obtain a product license from the Thai Food and Drug Administration (FDA).

On September 4, 2024, the Thai FDA announced guidelines specifically for powdered kratom leaves and kratom leaf extracts (using water or ethanol as solvents) as ingredients in food supplements. These guidelines aim to provide business operators with a clear framework for launching kratom-based food products in Thailand.

Key points from these guidelines include:

  • Raw material specifications and standards: Powdered kratom leaves and kratom leaf extracts must contain at least the prescribed amount of mitragynine (one of the primary active compounds in kratom) as a marker of quality. For example, mitragynine must account for at least 1% by mass for powdered kratom leaves.
  • Food supplement specification and standards: Food supplements containing powdered kratom leaves or kratom leaf extracts must not have a dosage of over 0.2 mg/day of mitragynine (including 7-hydroxymitraglynine, which may occur naturally), or 1 mg/day for food supplements containing kratom extracts that use water as a solvent. Addition of 7-hydroxymitraglynine to food supplements is prohibited.

    Mitragynine content in food supplement products must not exceed the specified dosage limit. Additionally, the food supplement product must be in a ready-to-eat form (e.g., liquid, gel, tablet, or capsule).

    If powdered kratom leaves or kratom leaf extracts are to be used as ingredients in food categories other than food supplements, a safety assessment must be conducted prior to their use, ensuring compliance with the necessary health and safety standards.

  • Manufacturing practices: The manufacturing locations of dietary supplements containing Kratom must comply with good manufacturing practice (GMP) standards, as specified in the annex to the Ministry of Public Health Announcement (No. 420) B.E. 2563 (2020) Re: Food Production Processes, Processing Equipment/Utensils and Storage Practices.
  • Labeling and warning statements: The labels of food supplements containing powdered kratom leaves or kratom leaf extracts must comply with the Notification of the Ministry of Public Health Re: Labeling and Food Supplement Products. The labels must also display the following warning statements:
    • Must not be consumed continuously for more than seven days.
    • Do not use this product in conjunction with other products containing kratom.
    • Must not be consumed with products containing alcohol.

    Additionally, there must be statements regarding prohibited usage for high-risk consumers. For example, products must not be used in patients with cardiovascular diseases, diabetes, or psychiatric disorders.

  • Approval process: Requests for approval of food supplement products containing powdered kratom leaves and kratom leaf extracts can be submitted online through the Thai FDA’s e-submission system. Submissions must include the product specifications, standards, and conditions of use in accordance with the established guidelines. Additionally, a laboratory report detailing the mitragynine content must be provided to the Thai FDA during the product registration process. If the product is imported, a certificate on the food standards of the manufacturing practices of the overseas manufacturer must be provided as part of the registration process.

Kratom as an Herbal Product
In addition to food products, kratom can also be approved as an herbal product under the Thai FDA’s Herbal Product Division. The requirements for registering kratom products as herbal products are distinct and include:

  • Herbal product specifications and standards: Kratom used in herbal products must adhere to strict quality and purity standards. This includes thorough testing for contaminants and verification of active ingredient concentrations. These stringent requirements ensure the safety and efficacy of kratom herbal products for consumers.

    The Herbal Product Division also provides guidelines for the registration of kratom leaf concentrates extracted using water and kratom leaf aqueous solutions. The guidelines specify that the amount of mitragynine must not exceed one milligram per day.

  • Manufacturing practices: Producers must adhere to good manufacturing practices (GMP) to ensure the consistency, safety, and efficacy of the herbal products. For importers, the manufacturing site is required to obtain GMP clearance verifying the standards of the overseas manufacturer, which must be equivalent or greater than the GMP standards in Thailand.
  • Labeling, leaflets, and packaging: Herbal products must have clear and informative labels that include dosage instructions, potential side effects, and contraindications. Kratom product labels and leaflets must have additional warnings or precautions as required to ensure the safety of the kratom usage. For instance, kratom products classified as herbal products for health promotion must display additional warning statements similar to the statements for food supplements mentioned above. Additionally, leaflets must contain contraindications to avoid safety issues, such as prohibiting the use of kratom products in people taking anticoagulants. These statements must comply with the guidelines issued by the Herbal Product Division.
  • Approval process: The approval process for herbal products involves submitting an application that includes product samples, safety data, and evidence of efficacy to the Herbal Product Division. The submitted documents must demonstrate that the products are safe for use and must provide evidence of the claimed health benefits.

Market Implications

The approval of kratom as a food or herbal product presents significant opportunities for both local and international producers. In Thailand, the number of approved kratom products remains relatively low, indicating substantial room for market expansion. Businesses can now legally cultivate, produce, and sell kratom if they adhere to the regulatory standards set by the Thai FDA. This regulatory clarity is anticipated to stimulate growth in the kratom market in terms of both domestic sales and export potential.

For further information on Thailand’s laws and regulations on kratom products, please contact Dr. Atthachai Homhuan at [email protected], Ravi Pinkoh at [email protected], or Sonatree Sehamontree at [email protected].

Related Professionals

Industries

Life Sciences

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

March 30, 2026
In response to an emerging crisis on food safety, the government of Vietnam promulgated Decree No. 46/2026/ND-CP (Decree 46) on January 26, 2026, and Resolution No. 66.13/2026/NQ-CP (Resolution 66.13) on January 27, 2026, setting out a number of substantive changes to the procedure and strict requirements for the declaration, registration, and importation of food products. Both instruments took effect upon issuance. However, shortly after they entered into force, food businesses encountered significant implementation challenges, particularly with respect to state inspection procedures at the customs clearance stage for imported products. In response, the government issued Resolution No. 09/2026/NQ-CP (Resolution 09) on February 4, 2026, temporarily suspending Decree 46 and Resolution 66.13 until a new effective date of April 16, 2026. Continued Suspension of Implementation of Decree 46 and Resolution 66.13 After considering feedback gathered by the Ministry of Health from food businesses and other stakeholders during the suspension period, the Vietnam Government Office issued a notice on March 20, 2026, agreeing to extend the suspension until the issuance of an amended Law on Food Safety and its guiding decree. Following this notice, on March 22, 2026, the Ministry of Health prepared a draft resolution to implement the notice and replace Resolution 09. Under the draft resolution, the effectiveness of Decree 46 and Resolution No. 66.13 would continue to be suspended until the amended Law on Food Safety takes effect, except for the provisions under Resolution 66.13 allowing flexibility in documents evidencing product efficacy, which would take effect on April 16, 2026, and remain effective until the Law on Food Safety is replaced (but not later than February 28, 2027). Accordingly, for products subject to the registration declaration procedure, such as health supplements, efficacy may be substantiated by either (i) scientific evidence supporting the declared function and effects of the product
Read More
February 26, 2026
Laos’ Food and Drug Department (FDD) has been using a new online registration system for drugs since the beginning of the year. The system, which was implemented following the November 2025 issuance of Notice No. 5960/FDD, became the official pathway for submissions on January 1, 2026. Since that date, paper-based registrations have no longer been accepted. This marks a significant advancement in the digitalization of regulatory processes in Laos. As the online system is now the exclusive platform for registration, renewal, and amendments, companies that have not yet aligned their processes to the new system should act promptly to ensure a smooth transition. To assist with this, the FDD will conduct periodic training sessions on the use of the online registration system, which will be delivered either in person or remotely, depending on operator demand. To start using the system, drug and medical device manufacturers, as well as import-export companies, that have not yet registered must submit a formal request identifying the authorized personnel who will access the platform, after which they will be issued user accounts and access codes. Each request must be accompanied by the company’s enterprise registration certificate (incorporation certificate), a copy of the identity card or passport of each designated user, and a scanned copy of their signature. There is no restriction on the number of users per company, allowing flexibility to meet operational needs. Companies that already hold accounts and access codes from the trial phase may continue using them and may apply for additional accounts if needed. Additional Requirements The new system also introduces a standardized format for drug registration numbers. For example, an import drug registration number such as 06 I 4040/15 will be changed to 06-IM-04040-15, and a domestic drug registration number such as 06 L 4040/15 will be changed to
Read More
January 21, 2026
Spurred by global geopolitics and Canada’s Indo-Pacific Strategy, which aims to forge deeper ties with ASEAN, Canadian companies have been showing growing interest in Thailand and Southeast Asia in recent years. To understand the opportunities offered by the region, we sat down with Andrew Stoutley, a Toronto native and the chief operating officer of Tilleke & Gibbins, a leading Southeast Asian regional law firm with over 130 years of history in Thailand. Q: Why are Canadian companies looking at Thailand and Southeast Asia right now? A: Two reasons stand out. First, diversification has moved up the agenda. Many Canadian companies want options outside North America due to tariff volatility and policy uncertainty in the United States, as well as questions around the next Canada–United States–Mexico Agreement mandatory joint review. At the same time, the shift of global production from China to Southeast Asia is accelerating, driven by rising costs, geopolitics, and the need to avoid overreliance on a single market. As a result, Canadian companies are looking for a second production base or a regional hub, and Thailand and its neighbors are natural choices given their manufacturing depth, location, and established supply chains. Second, Canada’s own efforts in the region are gaining traction. The Indo-Pacific Strategy has led to more on-the-ground support, including larger trade missions, upgraded diplomatic posts, and new financing options. Export Development Canada (EDC) now has a presence in Bangkok, giving Canadian companies a direct line to financing and insurance in Thailand. There’s also steady progress on trade frameworks like the recently signed Canada–Indonesia Comprehensive Economic Partnership Agreement (which will come into effect pending domestic procedures), ongoing negotiations of a Canada–ASEAN FTA, and the exciting announcement about the launch of negotiations of a Canada–Thailand FTA. Together, these developments have the potential to make it much easier
Read More
January 8, 2026
Thailand’s approach to cannabis regulation has moved quickly from broad access to a medical, prescription‑only system. The latest government regulation classifies the cannabis flower as a controlled herb under the Thai Traditional Medicine Wisdom Act. The latest rules ban advertising and recreational sales, allow sales only to patients with prescriptions (up to 30 days), and require flowers to come from GACP‑certified (Good Agricultural and Collection Practices) farms. More importantly, cannabis dispensaries can only sell to patients presenting valid prescriptions issued by one of seven professions—medical doctors, Thai traditional practitioners, applied Thai traditional practitioners, traditional Chinese medicine practitioners, pharmacists, dentists, and folk healers—consistent with approved clinical indications. Noncompliance risks license suspension or revocation, and criminal penalties of up to one year’s imprisonment or a THB 20,000 fine. The dispensary‑only model that proliferated in Thailand in recent years is expected to end soon, as the rules will push all cannabis dispensaries into medical settings or retail pharmacies. Dispensaries must convert into medical establishments—clinics, pharmacies, or traditional pharmacies—complete with on‑site licensed practitioners as well as budtenders; strong controls for storage, hygiene, odor, and smoke; and facilities for record-keeping. All flowers dispensed or exported must come from GACP‑certified farms. If the government ends dispensaries outright and forces a conversion to clinics or pharmacies, compensation will not be automatic at the outset. As a result, business operators should plan for compliance and repurposing under the Medical Facilities Act, Modern Drug Act, and Herbal Product Act, which regulate medical clinics, modern pharmacies, and traditional medicine pharmacies, respectively. The table below summarizes the required licenses for clinics, pharmacies, and traditional medicine pharmacies selling cannabis flowers in Thailand. Aside from the specific listed licenses, all three types of establishments must also obtain a license to sell a controlled herb (cannabis flowers) from the Department of Thai Traditional
Read More